Pyxis Oncology (PYXS) Gets a Hold from William Blair
In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on Pyxis Oncology (PYXS – Research Report). The company’s ...
Nasdaq21d
Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Pyxis Oncology, Inc. announced that the FDA has granted Fast Track Designation for its drug PYX-201, aimed at treating adult patients with recurrent or metastatic head and neck squamous cell ...